Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study.
Kertes
P J
PJ
University of Ottawa Eye Institute, Ont.
Britton
W A
WA
Leonard
B C
BC
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002829:Choroid / Q000098:blood supply*; D004596:Electroretinography; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D010865:Pilot Projects; D011994:Recombinant Proteins; D012449:Safety; D014792:Visual Acuity; D014822:Vitreous Body
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins